Exposure to Glucocorticoids Increases Risk for New-Onset Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 11, 2024 -- Exposure to systemic glucocorticoids during hospitalization is associated with an increased risk for new-onset diabetes, according to a study presented at the annual of the European Association for the Study of Diabetes, held from Sept. 9 to 13 in Madrid.
Rajna Golubic, M.D., Ph.D., from the University of Oxford in the United Kingdom, and colleagues estimated the crude and age- and sex-adjusted incidence rate ratio (IRR) of new-onset diabetes arising during time exposed versus unexposed to systematic glucocorticoids. The analysis data set included 451,606 adults free from diabetes (median age, 52 years).
The researchers found that autoimmune/inflammatory diseases/infections were the most common indication for systemic glucocorticoids (65.3 percent). Overall, 1.8 and 0.8 percent of ever-exposed versus never-exposed individuals developed new-onset diabetes in the exposed and nonexposed time in years. The incidence rates were 51.9 and 18.5 per 100 person-years for the ever-exposed and never-exposed groups, respectively. The median length of stay in days was three and one for ever-exposed and never-exposed participants. For new-onset diabetes associated with glucocorticoids, the unadjusted and age- and sex-adjusted IRRs were 2.8 and 2.6, respectively.
"These latest results give clinical staff a better estimate of how likely new diabetes is to occur and could prompt doctors to plan clinical care more effectively to detect and manage new diabetes," Golubic said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Time-Restricted Eating Helps to Improve Diabetes Outcomes
FRIDAY, Sept. 13, 2024 -- Time-restricted eating (TRE) may improve diabetes outcomes, independent of energy intake, according to a study presented at the annual meeting of the...
Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
FRIDAY, Sept. 13, 2024 -- Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2 diabetes who have not received...
Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide
FRIDAY, Sept. 13, 2024 -- For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.